pharm-stream-recent-webinars

1. Building A Science- And Risk-Based Bio-Decontamination Strategy 10/5/2026

   Annex 1 has made bio-decontamination central to sterility assurance, with isolator and barrier cycles now expected to be designed, justified, and reviewed across their lifecycle.

2. Accelerating CHO Media Development: From Screening To AI Design 10/1/2026

   Discover how high-throughput screening, process analytics, and AI-guided modeling can help identify promising CHO media and feed combinations faster and support a more predictive approach.

3. Lessons In Building Connected Lab Operations Across Development And GMP 9/30/2026

   Building connected operations across development and GMP environments removes bottlenecks and ensures data integrity. Explore practical insights to scale and standardize your lab workflows.

4. APAC Scaling AAV manufacturing to 1000 L: strategies for robust and reproducible production 9/30/2026
5. Scaling AAV Manufacturing To 1000 L: Strategies For Robust And Reproducible Production 9/30/2026
6. Design Verification Done Right: Smarter Strategies For Prefillable Syringes 9/29/2026

   A practical framework for planning and justifying design verification programs for prefillable syringes, covering test selection, acceptance criteria, and sample-size rationale within a risk-based approach.

7. Evaluating Modular CAR T Manufacturing Workflows 9/28/2026

   As CAR T manufacturing scales, balancing throughput, flexibility, and cell quality becomes increasingly complex. Explore strategies for improving process control, reducing bottlenecks, and more.

8. How Sodium Hydroxide CIP Affects Column Performance And Resin Lifetime 9/24/2026

   Sodium hydroxide CIP is essential for column hygiene, but cleaning decisions carry real tradeoffs for resin longevity and long-term chromatography performance.

9. Annex 1 In Practice: Turning CCS Into Cleanroom Design 9/24/2026

   Learn how embedding a contamination control strategy into early facility design mitigates risk, protects product quality, and ensures regulatory compliance.

10. Breaking The Concentration Barrier: New Long-Term Stability And PK Data For Subcutaneous Nanotrastuzuma 9/22/2026

    Nanoparticle engineering enabled a 440 mg/mL trastuzumab suspension that clears viscosity and stability barriers limiting conventional high-dose subcutaneous biologics formulations.